Forest Laboratories

The US Federal Trade Commission took on the biopharmaceutical industry last year with a series of unusual enforcement actions challenging proposed mergers and industry patent listings. Stakeholders ar

The US Federal Trade Commission’s muscling into the arena of Orange Book patent listings could put pressure on the US Food and Drug Administration to finally issue guidance on whether sponsors can lis